What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-10-22 compared with 2022-08-17 · 43 added, 38 removed, 13 unchanged (86% of the section changed)

5 - MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

common stock is listed on the NYSE American LLC Exchange, where it trades under the symbol “DSS”.

Our common stock

is listed on the NYSE American LLC Exchange, where it trades under the symbol “DSS”.

of March 1, 2024, we had 310 record holders of our common stock.

This number does not include the number of persons whose

shares are in nominee or in “street name” accounts through brokers.

did not pay dividends during 2021 or 2020.

We anticipate that we will retain any earnings and other cash resources for investment in

our business.

The payment of dividends on our common stock is subject to the discretion of our board of directors and will depend on

our operations, financial position, financial requirements, general business conditions, restrictions imposed by financing arrangements,

if any, legal restrictions on the payment of dividends and other factors that our board of directors deems relevant.

the Company has announced its decision to issue shares of Impact BioMedical, Inc.

to its shareholders of record at a to be determined

record date that will correspond with the registration of Impact BioMedical’s common stock.

The Company announced that it intended

to issue four (4) shares of Impact BioMedical stock for each share of DSS common stock held by DSS shareholders (with the exception of

shares beneficially held by Alset International Ltd).

This number does not include the number

of persons whose shares are in nominee or in “street name” accounts through brokers.

We did not pay

dividends during 2022.

In 2023, we did not pay cash dividends.

In April 2023, DSS distributed to its shareholders two (2) shares of

its beneficially owned common stock of Sharing Services Global Corporation (OTC:

SHRG) for each share of DSS common stock owned.

August of 2023, the Company issued four (4) shares of Impact BioMedical, Inc., formerly a wholly-owned subsidiary of the Company, to

its shareholders of record on July 10, 2023.

The payment of dividends

on our common stock is subject to the discretion of our board of directors and will depend on our operations, financial position, financial

requirements, general business conditions, restrictions imposed by financing arrangements, if any, legal restrictions on the payment

of dividends and other factors that our board of directors deems relevant.

Authorized for Issuance Under Equity Compensation Plans

of December 31, 2021, securities issued and securities available for future issuance under both our 2013 and 2020 Employee, Director

and Consultant Equity Incentive Plan (the “Plans”) is as follows:

stock to be issued upon vesting

of securities to be issued upon exercise of outstanding options, warrants and rights

average exercise price of outstanding options, warrants and rights

of securities

available for

issuance (under

Equity compensation plans approved by security

2013 Employee,

Director and Consultant Equity Incentive Plan - options

2013 Employee, Director

and Consultant Equity Incentive Plan - warrants

As of December 31,

2023, securities issued and securities available for future issuance under both our 2013 and 2020 Employee, Director and Consultant Equity

Incentive Plan (the “Plans”) is as follows:

Restricted stock to be issued upon vesting

Number of securities to be issued upon exercise of outstanding options, warrants and rights

Weighted average exercise price of outstanding options, warrants and rights

Number of securities

remaining available for

future issuance (under equity compensation

Plans (excluding

securities reflected in

column (a & b))

Plan Category

Equity compensation plans approved by security holders

2013 Employee, Director and Consultant Equity Incentive Plan - options

2013 Employee, Director and Consultant Equity Incentive Plan - warrants

2020 Employee, Director and Consultant Equity Incentive Plan

warrants listed in the table above were issued to third party service providers in partial or full payment for services rendered and

in conjunction with third party funding agreements.

Issuances of Unregistered Securities

regarding any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act

of 1933, as amended, and was not included in a quarterly report on Form 10-Q or in a current report on Form 8-K, is set forth below.

Each such transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities

Act or Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted.

Information regarding

any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act of 1933,

as amended, and was not included in a quarterly report on Form 10-Q or in a current report on Form 8-K, is set forth below.

transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act or

Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted.

Unless stated otherwise:

(i) the securities were offered

and sold only to accredited investors;

(i) the securities were offered and

sold only to accredited investors;

(ii) there was no general solicitation or general advertising related to the offerings;

each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed

of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed

them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial

3 unchanged sentences

Repurchased by the Registrant

did not purchase or repurchase any of our securities in the fiscal year ended December 31, 2021, including the fourth quarter.

We did not purchase

or repurchase any of our securities in the fiscal year ended December 31, 2023.

6 - SELECTED FINANCIAL DATA

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K/A

Item 5. Market for Registrant’s Common Equity